Hypertension最新文献

{"title":"Validation Status of Electronic Sphygmomanometers in China: A National Survey.","authors":"Xianghui Zhang, Zhimin Xu, Yingchun Yao, Huilei Zheng, Jian Wu, Jingwen Hu, Shenggen Wu, Quanjun Lyu, Yong Liu, Min Wu, Liangxia Chen, Lina Xu, Haiyan Zhou, Peifen Duan, Jianghong Dai, Hong Ding, Shuang Wang, Yi Zhao, Jihong Hu, Liyue Zhu, Rong Hai, Baoliang Zhong, Huilian Zhu, Kui Li, Yao Lu, Shaowen Tang, Xingming Li, Yan Zhang, Zongtao Chen, Tongyu Wang, Mei Li, Fuxu Liu, Chengluan Liu, Xiaoling Yang, Lihua Dong, Jixiang Ma, Pei Gao, Wuxiang Xie, Yangfeng Wu","doi":"10.1161/HYPERTENSIONAHA.124.24203","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.124.24203","url":null,"abstract":"<p><strong>Background: </strong>Although the information on the validation status of electronic sphygmomanometer (ES) devices in use in health care institutions and households is much more clinically relevant than that of ES models available on the market, it remains insufficient.</p><p><strong>Methods: </strong>A national survey was conducted across all administrative regions of mainland China to assess the validation status of ESs. Fifty-eight cities were selected with stratification by municipality, provincial capital, and other cities, and health care institutions and households in each city were chosen by convenience to identify ES devices in use according to the study protocol. Information on devices' model, type, was collected. The validation status of each device was ascertained through searching international online registries of its models.</p><p><strong>Results: </strong>A total of 3230 ES devices (1924 from health care institutions and 1306 from households), encompassing 498 ES models, were actually selected. The weighted proportion of accuracy-validated devices was significantly higher in health care institutions (33.9% [95% CI, 31.8-36.0%]) compared with households (23.0% [95% CI, 20.8-25.4%]; <i>P</i><0.001), and both exceeded the proportions for models (17.7% [95% CI, 13.7-22.6%] and 12.5% [95% CI, 9.5-16.3%], respectively). Regional economic development, device type, and years in use were associated with the proportion of accuracy-validated devices. Notably, 8.8% of devices used in secondary hospitals were wrist type.</p><p><strong>Conclusions: </strong>The accuracy validation status of ESs in China in the number of devices in use shows a more favorable situation than that in the number of models but remains low and concerning. Policies are urgently needed to promote the widespread adoption of accuracy-validated models among all users.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142978302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time in Target Range for Blood Pressure and Adverse Health Outcomes: A Systematic Review.","authors":"Huairong Wang, Jialu Song, Zhike Liu, Huan Yu, Kun Wang, Xueying Qin, Yiqun Wu","doi":"10.1161/HYPERTENSIONAHA.124.24013","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.124.24013","url":null,"abstract":"<p><strong>Background: </strong>Blood pressure (BP) time in target range (TTR) reflects the proportion of time that BP measurement is within a specified target range. We aim to summarize the evidence for relationships between TTR and adverse health outcomes.</p><p><strong>Methods: </strong>Seven databases were searched. After quality assessment and data extraction, meta-analyses were performed to generate pooled estimates of the association (hazard ratios) between TTR and health outcomes. Primary outcomes were all-cause mortality and cardiovascular death. Secondary outcomes included major adverse cardiovascular events, myocardial infarction, stroke, heart failure, atrial fibrillation, and adverse kidney events.</p><p><strong>Results: </strong>In all, 21 studies were included, mostly rated at low risk of bias. TTR was defined by systolic BP (SBP) in 15 studies and by both SBP and diastolic BP in 6 studies. Per SD increase of TTR was associated with significantly decreased risks of all-cause mortality (110-130 mm Hg SBP TTR: hazard ratios, 0.85 [95% CI, 0.82-0.89]; 120-140 mm Hg SBP TTR: 0.81 [95% CI, 0.70-0.94]; and 70-80 mm Hg diastolic BP TTR: 0.88 [95% CI, 0.83-0.93]), cardiovascular death (110-130 mm Hg SBP TTR: 0.83 [95% CI, 0.78-0.87]; 120-140 mm Hg SBP TTR: 0.76 [95% CI, 0.65-0.89]; and 70-80 mm Hg diastolic BP TTR: 0.85 [95% CI, 0.80-0.90]), major adverse cardiovascular events (120-140 mm Hg SBP TTR: 0.76 [95% CI, 0.70-0.83]), and heart failure (110-130 mm Hg SBP TTR: 0.84 [95% CI, 0.76-0.93] and 120-140 mm Hg SBP TTR: 0.78 [95% CI, 0.68-0.89]). However, there was not sufficient support for the association of TTR with myocardial infarction, stroke, atrial fibrillation, or adverse kidney events.</p><p><strong>Conclusions: </strong>Higher TTR was associated with reduced risks of all-cause mortality, cardiovascular death, major adverse cardiovascular events, and heart failure, highlighting the importance of sustained BP control in clinical practice.</p><p><strong>Registration: </strong>URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42023486437.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NPA7: A Dual Receptor Activating Peptide That Inhibits Cardiac Oxidative Stress.","authors":"Xiaoyu Ma, J C Malsawmzuali, Dante G Moroni, Xiao Ma, Ye Zheng, Shuchong Pan, Ying Wang, S Jeson Sangaralingham, John C Burnett","doi":"10.1161/HYPERTENSIONAHA.124.23579","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.124.23579","url":null,"abstract":"<p><strong>Background: </strong>Cardiomyocyte oxidative stress significantly contributes to the progression of hypertension-induced heart failure, highlighting the need for targeted therapies. We developed a novel peptide, NPA7, that coactivates the GC-A (guanylyl cyclase A)/cGMP and MasR (Mas receptor)/cAMP pathway. This study aimed to test NPA7's ability to inhibit oxidative stress by modulating the p62-KEAP1 (Kelch-like ECH-associated protein 1)-NRF2 (nuclear factor erythroid 2-related factor 2) pathway in human cardiomyocytes (HCMs) and a rat model of hypertension.</p><p><strong>Methods: </strong>Oxidative stress was induced in HCMs using H₂O₂ with PBS or NPA7 treatment. Intracellular reactive oxygen species levels were assessed via dihydroethidium staining. Western blotting analysis measured p62, KEAP1, and NRF2 protein levels, while GSH/GSSG ratios and antioxidant gene expression were analyzed. HCMs were transfected with siRNA targeting GC-A, MasR, or p62 before NPA7 and H₂O₂ treatment. In vivo, spontaneously hypertensive rats received saline or NPA7, with normotensive WKY rats as control and cardiac oxidative stress, KEAP1 protein levels, NOX2, and p67 mRNA levels were measured.</p><p><strong>Results: </strong>NPA7 reduced H₂O₂-induced reactive oxygen species levels and increased GSH/GSSG ratio in HCMs. Silencing GC-A and MasR reversed NPA7's effects. NPA7 activated the KEAP1-NRF2 pathway, enhancing NRF2's antioxidant target gene expression. In p62 knockdown HCMs, NPA7-induced KEAP1 degradation and NRF2 activation were diminished. Reactive oxygen species levels were elevated in spontaneously hypertensive rat versus WKY hearts however, NPA7 treatment reduced myocardial reactive oxygen species, suppressed KEAP1 protein, and decreased NOX2 and p67 mRNA levels.</p><p><strong>Conclusions: </strong>NPA7 exhibits antioxidant properties in HCMs and spontaneously hypertensive rat hearts by targeting GC-A and MasR through the p62-KEAP1-NRF2 pathway, supporting a novel therapeutic approach against cardiovascular disease-related oxidative stress.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deficiency of Endothelial <i>Piezo2</i> Impairs Pulmonary Vascular Angiogenesis and Predisposes Pulmonary Hypertension.","authors":"Feng Wei, Ziying Lin, Wenju Lu, Haiyun Luo, Huazhuo Feng, Shiyun Liu, Chenting Zhang, Yulin Zheng, Chen Jiyuan, Shaocong Mo, Chen Wang, Zizhou Zhang, Wei Feng, Junqi Zhu, Qifeng Yang, Min Du, Weiguo Kong, Aofeng Liu, Jiaxuan Lai, Xiang Li, Xuefen Wu, Ning Lai, Yuqin Chen, Kai Yang, Jian Wang","doi":"10.1161/HYPERTENSIONAHA.124.22948","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.124.22948","url":null,"abstract":"<p><strong>Background: </strong>Mechanosensitive Piezo1 channel plays a key role in pulmonary hypertension (PH). However, the role of Piezo2 in PH remains unclear.</p><p><strong>Methods: </strong>Endothelial cell (EC)-specific <i>Piezo2</i> knockout (<i>Piezo2</i>^flox/flox, Tek-Cre⁺; <i>Piezo2^EC-/-</i>) rats and primarily cultured pulmonary microvascular ECs were used to determine the role of Piezo2 in PH.</p><p><strong>Results: </strong>Data analysis of publicly accessible single-cell RNA-sequencing data sets uncovered significant downregulation of Piezo2 in lung ECs from patients with idiopathic pulmonary arterial hypertension, which was verified in the lungs/ECs from PH rat models induced by hypoxia or monocrotaline. Comparing to wild-type rats, <i>Piezo2</i>^<i>EC</i>^<i>-/-</i> rats exhibited exacerbated PH in both hypoxia-induced PH and monocrotaline-induced PH, characterized by the worsened hemodynamical and histological changes. <i>Piezo2</i>^<i>EC</i>^<i>-/-</i> rats showed dramatic loss of pulmonary microvessels, in association with the decreased intracellular free calcium concentration ([Ca²⁺]_i) and downregulation of VEGFR2 (vascular endothelial growth factor receptor 2) and phosphorylated SRF (serum response factor) in pulmonary microvascular ECs. Knockout of <i>Piezo2</i> or treatment with a calcium chelator, EDTA, impaired the ability of tube formation and migration in pulmonary microvascular ECs, which was restored by supplementation of extra calcium. A safflower oil diet rich in linoleic acid, which can enhance the stability and function of Piezo2, effectively alleviated PH development in a hypoxia-induced PH rat model.</p><p><strong>Conclusions: </strong>This study demonstrates that EC-specific knockout of <i>Piezo2</i> exacerbates PH pathogenesis, at least partially, through the suppression of [Ca²⁺]_i/phosphorylated SRF/VEGFR2 signaling axis in pulmonary vascular ECs. Targeted activation of Piezo2 could be a novel effective strategy for the treatment of PH.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Obesity Prevalence Among Adults With Hypertension in the United States, 2001 to 2023.","authors":"Jiabin Tu, Hongkui Chen, Qingfeng Zeng, Liling Chen, Yansong Guo, Kaihong Chen","doi":"10.1161/HYPERTENSIONAHA.124.24123","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.124.24123","url":null,"abstract":"<p><strong>Background: </strong>Obesity is a factor contributing to the occurrence of hypertension and a risk factor for adverse outcomes in populations with hypertension. The changes in the prevalence of obesity in populations with hypertension remain unclear. Investigating the changes in the prevalence of obesity in populations with hypertension can provide information for the treatment and management of hypertension.</p><p><strong>Methods: </strong>The clinical data from adults aged ≥20 years with hypertension were extracted from the National Health and Nutrition Examination Survey 2001 to 2023. The primary outcome was the prevalence of obesity (body mass index≥30 kg/m²). The trend in the prevalence of obesity among American adults with hypertension was evaluated via a trend test.</p><p><strong>Results: </strong>The age-standardized prevalence of obesity among populations with hypertension in America increased from 39.6% in 2001 to 55.4% in 2023 (<i>P</i> for trend<0.001). This trend was observed in male (35.4%-53.6%; <i>P</i> for trend<0.001) and female (45.6%-57.7%; <i>P</i> for trend<0.001) populations with hypertension. While the prevalence of grade II (35 kg/m²≤body mass index<40 kg/m²) and grade III obesity (body mass index≥40 kg/m²) increased significantly in both sexes, the prevalence of grade I obesity (30 kg/m²≤body mass index<35 kg/m²) increased significantly only in males (23.2%-30.0%; <i>P</i> for trend=0.003) and did not significantly change in females (22.2%-21.7%; <i>P</i> for trend=0.135).</p><p><strong>Conclusions: </strong>The prevalence of obesity among American adults with hypertension increased from 2001 to 2023. In males, the prevalence of grades I, II, and III obesity increased. Among females, the prevalence of only grades II and III obesity increased.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reproducibility and Treatment Effect on Office and Ambulatory Pressure Relation.","authors":"Giuseppe Mancia, Rita Facchetti, Fosca Quarti-Trevano, Guido Grassi","doi":"10.1161/HYPERTENSIONAHA.124.23549","DOIUrl":"10.1161/HYPERTENSIONAHA.124.23549","url":null,"abstract":"<p><strong>Background: </strong>In the absence of outcome-based ambulatory blood pressure (BP) trails hypertension guidelines provide 24-hour mean BP values corresponding to trial-validated office BP values. Data are shown for untreated and treated patients together, but whether corresponding ambulatory values are similar in untreated and treated hypertensives and reproducible at yearly measurements during treatment is undefined.</p><p><strong>Methods: </strong>In 2397 patients of the ELSA (European Lacidipine Study on Atherosclerosis) and PHYLLIS (Plaque Hypertension Lipid-Lowering Italian Study) trials, we calculated the office and 24-hour BP relationship according to the linear regression model, with office systolic BP as the independent variable, at baseline and yearly during a 3-year treatment. Twenty-four hour BP values corresponding to clinically important office BP values (hypertension grading and treatment thresholds and targets) were calculated and compared with those provided by guidelines.</p><p><strong>Results: </strong>Office and 24-hour systolic BP or diastolic BP always exhibited a significant linear relationship, with, however, limited Pearson correlation coefficients (never >0.44).The slopes of the relationship were superimposable between different years of treatment but always significantly less steep than the slope seen in untreated individuals. Compared with the guideline-provided corresponding values, 24-hour BP showed qualitative and quantitative differences; for example, it was considerably lower and higher than the guideline-corresponding values when office BP was in the high hypertension and low treatment target ranges, respectively.</p><p><strong>Conclusions: </strong>In treated patients with hypertension the slope of the office and 24-hour BP linear regression is reproducible over time. However, the slopes are steeper in untreated individuals, indicating that information on ambulatory BP values corresponding to office BP values can be more accurate if separately estimated in these 2 conditions.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"126-135"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats.","authors":"Soumiya Pal, Ashim K Bagchi, David S Henry, Reid D Landes, Shengyu Mu, Sung W Rhee, Nancy J Rusch, Amanda J Stolarz","doi":"10.1161/HYPERTENSIONAHA.124.23194","DOIUrl":"10.1161/HYPERTENSIONAHA.124.23194","url":null,"abstract":"<p><strong>Background: </strong>Hypertension increases the risk of lymphedema in patients with comorbidities, but whether hypertension directly compromises lymph vessel (LV) function and lymph flow is unclear. We compared the contractions of mesenteric LVs ex vivo and lymph flow in vivo between normotensive and Ang II (angiotensin II)-induced hypertensive rats and explored the ionic basis of contractile patterns. Key studies were recapitulated in spontaneously hypertensive rats and control Wistar-Kyoto rats.</p><p><strong>Methods: </strong>Video microscopy continuously recorded the diameters of cannulated rat mesenteric LVs, and high-speed optical imaging estimated mesenteric lymph flow in vivo. Jess capillary Western electrophoresis evaluated expression levels of ion channel proteins.</p><p><strong>Results: </strong>Isolated LVs from Ang II-induced hypertensive rats exhibited dysrhythmic contractions, whereas LVs from both Ang II-induced hypertensive rats and spontaneously hypertensive rats exhibited reduced diastolic diameters and cross-sectional flow. Mesenteric lymph flow in vivo was 2.9-fold lower in Ang II-induced hypertensive rats compared with normotensive rats. Surprisingly, the LVs from Ang II-induced hypertensive rats expressed fewer intact L-type Ca²⁺ channel pore proteins and more modulatory cleaved C-terminal fragments. However, pharmacological block of voltage-gated K⁺ channels but not other K⁺ channel types in control LVs established the pattern of contractile dysfunction observed in hypertension. Jess capillary Western electrophoresis analysis confirmed a loss of Shaker-type K_V1.2 channels in LVs from hypertensive rats.</p><p><strong>Conclusions: </strong>We provide initial evidence of lymphatic contractile dysfunction and compromised lymph flow in hypertensive rats, which may be caused by a loss of K_V1.2 channels in the lymphatic muscle cells.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"72-83"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exposure to Volatile Organic Compounds and Blood Pressure in NHANES 2011 to 2018.","authors":"Katlyn E McGraw, Arce Domingo-Relloso, Daniel W Riggs, Danielle N Medgyesi, Raghavee Neupane, Jeanette A Stingone, Tiffany R Sanchez","doi":"10.1161/HYPERTENSIONAHA.124.23695","DOIUrl":"10.1161/HYPERTENSIONAHA.124.23695","url":null,"abstract":"<p><strong>Background: </strong>Volatile organic compounds (VOCs) are ubiquitous environmental pollutants. Exposure to VOCs is associated with cardiovascular disease risk factors, including elevated blood pressure in susceptible populations. However, research in the general population, particularly among nonsmoking adults, is limited. We hypothesized that higher VOC exposure is associated with higher blood pressure and hypertension, among nonsmokers.</p><p><strong>Methods: </strong>We included 4 cycles of data (2011-2018) of nonsmoking adults (n=4430) from the National Health and Nutrition Examination Survey. Urinary VOC metabolites were measured by ultraperformance liquid chromatography-mass spectrometry, adjusted for urine dilution, and log-transformed. We estimated mean differences in blood pressure using linear models and prevalence ratio of stage 2 hypertension using modified Poisson models with robust standard errors. Models were adjusted for age, sex, race and ethnicity, education, body mass index, estimated glomerular filtration rate, and National Health and Nutrition Examination Survey cycle.</p><p><strong>Results: </strong>Participants were 54% female, with a median age of 48 years, 32.3% had hypertension, and 7.9% had diabetes. The mean differences (95% CI) in systolic blood pressure were 1.61 (0.07-3.15) and 2.46 (1.01-3.92) mm Hg when comparing the highest with the lowest quartile of urinary acrolein (N-acetyl-S-[2-carboxyethyl]-L-cysteine) and 1,3-butadiene (N-acetyl-S-[3,4-dihydroxybutyl]-L-cysteine) metabolites. The prevalence ratios for hypertension were 1.06 (95% CI, 1.02-1.09) and 1.05 (95% CI, 1.01-1.09) when comparing the highest with lowest quartiles of urinary acrolein (N-acetyl-S-[2-carboxyethyl]-L-cysteine) and 1,3-butadiene (N-acetyl-S-[3,4-dihydroxybutyl]-L-cysteine), respectively.</p><p><strong>Conclusions: </strong>Exposure to VOCs may be a relevant yet understudied environmental contributor to cardiovascular disease risk in the nonsmoking, US population.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"136-148"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11655251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endothelial Cell TRPV4 Channels Turn to the Dark Side During Hypertension.","authors":"Alejandro Mata-Daboin, Jonathan H Jaggar","doi":"10.1161/HYPERTENSIONAHA.124.24124","DOIUrl":"10.1161/HYPERTENSIONAHA.124.24124","url":null,"abstract":"","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":"82 1","pages":"69-71"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11658793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"To Harmonize or to Hinder … Do We Need 2 Sets of European Hypertension Guidelines in 2024?","authors":"Aletta E Schutte, Garry L R Jennings","doi":"10.1161/HYPERTENSIONAHA.124.23722","DOIUrl":"10.1161/HYPERTENSIONAHA.124.23722","url":null,"abstract":"","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"8-10"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142285904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}